News from targetedonc.com
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top targetedonc.com News

Cancer · San Francisco(MedPage Today) -- SAN FRANCISCO -- Adding modified FOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) and bevacizumab (Avastin) to atezolizumab (Tecentriq) significantly improved progression-free survival (PFS) in patients with previously untreated...See the Story
Regimen Improves PFS in Highly Mutated Metastatic Colorectal Cancer
100% Center coverage: 1 sources

United States · United StatesTargeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.See the Story
